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Angiogenesis in melanoma and various carcinomas often corre-
lates with the likelihood of the development of metastases and the
prognosis of such patients (Weidner et al, 1991; Folkman, 1995b;
Weidner, 1995; Erhard et al, 1997; Schiffenbauer et al, 1997). A
number of different angiogenic and anti-angiogenic factors are
known to be involved in regulation of the angiogenic cascade,
including vascular endothelial growth factor (VEGF), acidic and
basic fibroblast growth factor (bFGF), hepatocyte growth factor
(scatter factor), platelet-derived growth factor, transforming
growth factor-b1, interleukin-8 (IL-8), tumour necrosis factor-a
(TNF-a), SPARC peptides, angiostatin and interferon-a
(Bussolino et al, 1996). These and other cytokines produced by
endothelial cells can stimulate tumour cells in a paracrine manner
(Hamada et al, 1992). Furthermore, normal endothelial cells
within the tumour mass may be abnormally stimulated by
diffusible growth factors released by tumour cells (Folkman,
1995a).
Angiogenesis inhibitors are now under investigation in patients
(Burrows and Thorpe, 1994; Folkman, 1995b; Ziegler, 1996).
These include the commercially available agents Thalidomide,
interferon-a, paclitaxel, tamoxifen and medroxyprogesterone
acetate, and experimental agents including neutralizing humanized
antibodies to VEGF and bFGF, metalloproteinase inhibitors,
TMP-470 (a synthetic analogue of fumagillin) and IL-12 (Ingber
et al, 1990; D’Amato et al, 1994; Voest et al, 1995; Gasparini,
1996; Talbot and Brown, 1996). Anti-angiogenic therapy appears
to have its optimum efficacy if given daily or intermittently over a
long period, acts mainly on proliferating capillary endothelial
cells, is generally of low toxicity and, in long-term animal studies,
drug resistance has not developed (Folkman, 1995b).
Thalidomide is known to have powerful anti-angiogenic activity
(D’Amato et al, 1994; Battegay, 1995), can eradicate experimental
tumours in mice (Ching et al, 1995) and is used to treat the
vascular tumour Kaposi’s sarcoma with 60% of patients
responding or achieving stable disease (Ziegler, 1996). Non-
malignant indications for Thalidomide include retinal neo-vascu-
larization due to macular degeneration, leprosy, Crohn’s disease,
pulmonary tuberculosis, recurrent graft-versus-host disease and
human immuno-deficiency virus-related oral aphthous ulcers
(Vogelsang et al, 1992; Asscher, 1994; Crawford, 1994; Folkman,
1995a; Tramontana et al, 1995; Jacobson et al, 1997; Wettstein
and Meagher, 1997). The notorious teratogenic effects of
Thalidomide when administered to women in the first trimester of
pregnancy in the 1960s (McBride, 1961; Lenz, 1962) have been
attributed to inhibition of blood vessel growth in the developing
fetal limb bud (D’Amato et al, 1994) and more recently to free
radical-mediated oxidative DNA damage (Parman et al, 1999).
Thalidomide increases the degradation of the mRNA of a
number of peptide-signalling molecules such as FGF (D’Amato et
al, 1994) and TNF-a (Ching et al, 1995). The suppression of TNF-
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high levels of TNF-ahave previously been linked to cachexia and
tumour-related malaise (Yoneda et al, 1991; Haslett, 1998).
The present phase II study assessed the efficacy and toxicity 
of continuous Thalidomide in the treatment of patients with
metastatic melanoma, renal cell carcinoma and ovarian and breast
cancer. In view of the dose-related peripheral sensory neuropathy
found in patients on long-term Thalidomide, we chose to employ
the low dose of Thalidomide 100mg orally every night in this
group of patients, many of whom had previously received neuro-
toxic chemotherapy, and to follow all patients with electrophysio-
logical studies before and during therapy (Fullerton and Kremer,
1961; Powell and Gardner-Medwin, 1994). Although lower than
most doses employed for shorter periods, experience from treating
Behçet’s syndrome suggests that a Thalidomide dose as low as 
25mg daily is clinically active (Eisenbud et al, 1987). As well as
recording the palliative benefits and objective clinical responses 
to Thalidomide, we assessed biological responses by serially
measuring serum TNF-aand serum and urinary VEGF and bFGF
before and during treatment.
MATERIALS AND METHODS
Patients
Patients with histologically confirmed metastatic renal cell carci-
noma, melanoma, ovarian cancer or breast cancer, were eligible for
entry into this study. Eligibility criteria included the presence of
metastatic disease that was measurable in at least one diameter
greater than 1cm by clinical examination or imaging. The disease
must have shown progression between two recorded time points and
be defined clinically or by imaging. Patients must not have received
endocrine therapy, radiotherapy, biological agents or chemotherapy
in the previous 4 weeks. Marker lesions must not have received
radiotherapy at any time. Patients had to be of ECOG performance
status 0–2. All patients had to be older than 18 years and had a life
expectancy of greater than 12 weeks. Patients required adequate
bone marrow reserve with white blood count greater than 3 ´109 l–1,
platelets greater than 100 ´109 l–1, and haemoglobin more than 10g
dl–1, normal renal function or a glomerular filtration rate greater than
60ml min–1 as assessed by EDTA clearance and adequate hepatic
function defined as liver function tests less than twice the normal
values, unless due to metastatic disease. Female patients had to have
a negative pregnancy test. Any women of child-bearing age had to
use adequate contraceptive methods during the study. In view of the
anti-angiogenic action of Thalidomide, any wound must have healed
and any surgery other than a skin biopsy must have been performed
more than 4 weeks prior to study entry. Patients with pre-existing
peripheral neuropathy of WHO grade 2 or greater were not eligible
for the study.
The protocol was approved by the Royal Marsden Hospital
Ethics Committee and all patients gave written informed consent.
Treatment
Following baseline assessment at study entry, patients started
taking Thalidomide 100mg (Penn Pharmaceuticals Ltd, Gwent,
UK) orally every night. Treatment continued until there was
evidence of disease progression or unacceptable toxicity was
encountered, or the patient wished to stop treatment for any reason.
Assessment of response and toxicity
All patients were examined clinically before treatment. Baseline
laboratory investigations included full blood count, serum
biochemistry, sensory nerve action potential (SNAP), serum and
urine were frozen and stored for bFGF, VEGF and TNF-aassess-
ment by enzyme-linked immunosorbent assay (ELISA) (R&D
Systems, Abingdon, UK), electrocardiogram and serum pregnancy
test for women of child-bearing age. Patients underwent imaging or
clinical measurement as appropriate to assess their disease status at
the start of treatment. Patients completed a symptom distress scale
(HAD and Rotterdam scores) before starting treatment.
Patients had a clinical examination, full blood count and
biochemistry every month whilst on treatment. Patients received a
SNAP test, serum and urine were frozen and stored for bFGF,
VEGF and TNF-aassessment, clinical imaging, symptom distress
scale questionnaire and toxicity evaluation at 1, 3, 6, 9 and 12
months while on treatment.
Response was assessed according to standard International
Union Against Cancer criteria following clinical measurement or
imaging. Toxicity was assessed according to WHO criteria at each
assessment visit (Millar et al, 1981). Patients who received at least
4 weeks of treatment were assessable for response and all patients
were assessable for toxicity. The response duration was defined as
the time elapsed between start of treatment with Thalidomide and
the date of progressive disease or last follow-up evaluation. Stable
disease was defined as where neither partial response nor progres-
sive disease could be established.
Statistical considerations
The threshold response rate for each individual tumour type below
which the treatment would be considered ineffective was 15%. It
was originally intended to recruit 19 patients for each tumour type.
If there were no responses in these patients the study would be
terminated. There was only a 5% chance that this would occur if
the true response rate was 15%. We decided to terminate the study
before full recruitment had been completed because of the
responses seen and because of slow recruitment of patients with
breast cancer. The c2 test and McNemar test for trend were used to
assess differences in quality of life before and during treatment
with Thalidomide.
RESULTS
Patient characteristics
Between July 1997 and March 1998, 66 eligible patients with
advanced solid tumours under the care of the Royal Marsden
Hospital, London and Sutton, were entered into the study; 19
patients had ovarian cancer, 13 men and five women had renal
carcinoma, 12 men and five women had melanoma and 12 women
had breast cancer (Table 1). Two other patients with melanoma
were also entered but were found not to be eligible because, on
review of radiological imaging, they showed a late response to
biochemotherapy given prior to entering the study. The median age
of patients was 48 years, range 33–62 years. The majority of
patients were fit, with ten having a performance status of 0 and 38
having a performance status of 1. However, 18 patients had a
performance status of 2. Many of the patients had received
multiple treatments before entering the study.
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All 66 eligible patients entered into the study were evaluable for
response and toxicity (Table 2). Three partial responses were 
seen in the 18 patients treated for renal carcinoma. One response
lasted 5 months, the other two partial responses are continuing 
at 5 and 11 months of follow-up. The response continuing at 
11 months was dramatic and is illustrated in Figure 1. This patient
had progressed rapidly on biochemotherapy with neck
lymphadenopathy and symptomatic lung metastases and had
severe malaise before starting Thalidomide. Within 24 h of
starting Thalidomide his malaise had resolved and his perfor-
mance status had improved to 0. Over the next 5 months his lung
and lymph node metastases shrunk and a bronchoscopic biopsy of
the largest lung metastasis at 11 months showed necrotic tumour
only. It was also noticeable in the group with renal carcinoma that
13 patients experienced stabilization of their previously progres-
sive disease: three of these patients had stable disease for 3 months
or longer, whilst the other ten patients had stable disease for only
1–3 months.
Of the remaining 48 patients with melanoma, ovarian carci-
noma or breast carcinoma none showed any objective tumour
response to treatment with Thalidomide. However, three patients
had a differential response and one patient with rapidly progres-
sive skin deposits of melanoma on his leg experienced sympto-
matic improvement and was able to walk more than 100 yards,
having previously been chair-bound.
Angiogenic markers
A wide range of serum and urinary VEGF levels was found in
patients and in two controls (Table 3). No clear relationship between
the absolute level of VEGF and tumour response was found, nor
were there any clear differences between different tumour types.
However, a rising VEGF level was associated with progressive
disease in six of 11 patients who had serial measurements.
bFGF was only detected in the serum of 12 patients all of whom
had early progressive disease. bFGF and free TNF-a were not
detected in the urine of any patient. Free TNF-a was detected in
the serum of one patient with melanoma, one patient with breast
cancer and one patient with ovarian cancer.
Toxicity and symptomatic side-effects
Thalidomide 100 mg orally every night was generally very well
tolerated with no WHO grade 3 or 4 toxicities (Table 4). The main
toxicity was lethargy (38 patients grade 1 and eight patients grade
2). Grade 2 peripheral neuropathy was detected clinically in two
patients who had been on treatment for 11 months. On interrupting
Thalidomide, the neuropathy resolved and treatment recom-
menced at 50 mg each night. All patients had SNAP tests and no
other patient developed sensory neuropathy. One patient devel-
oped a WHO grade 2 headache shortly after starting Thalidomide
and another developed WHO grade 2 peripheral oedema. Both
side-effects resolved on stopping Thalidomide. Ten patients devel-
oped WHO grade 1 constipation and two developed an itchy 
WHO grade 1 skin rash. These side-effects responded to standard
measures.
814 T Eisen et al
British Journal of Cancer (2000) 82(4), 812–817 © 2000 Cancer Research Campaign
Table 1 Patient characteristics
Number of patients 66
Ovary 19
Renal 18
Melanoma 17
Breast 12
Male 29
Female 37
Age (years)
Median 48
Range (33–62)
Performance status
01 0
13 8
21 8
Previous treatment
Chemotherapy 44
Radiotherapy 24
Surgery 22
Hormone 14
Immuno-chemotherapy 10
Immunotherapy 4
None 10
Table 2 Responses to Thalidomide
No. of patients Partial response Stable disease
(> 3 months)
Ovary 19 0 (0%) 1 (5%)
Renal 18 3 (17%) 3 (17%)
Melanoma 17 0 (0%) 1 (6%)
Breast 12 0 (0%) 0 (0%)
Table 3 Concentration of angiogenic markers in serum and urine before
and during Thalidomide therapy (pg ml–1)
Serum Controls Pre-Thalidomide On Thalidomide
n = 2 n = 41 (4–6 weeks of
treatment)
n = 23
Mean Range Mean Range Mean Range
VEGF 51 27–74 568 114–1861 554 110–1080
bFGF < 10 < 10 < 10 < 10–28 < 10 < 10–20
TNF-a < 10 < 10 < 10 < 10–16 < 10 < 10–20
Urine Controls Pre-Thalidomide On Thalidomide
n = 2 n = 31 (4–6 weeks of
treatment)
n = 13
Mean Range Mean Range Mean Range
VEGF 83 30–145 106 24–695 222 10–1000
bFGF < 10 < 10 < 10 < 10 < 10 < 10
TNF-a < 10 < 10 < 10 < 10 < 10 < 10
Table 4 Symptomatic side-effects
WHO grade 1 WHO grade 2
n (%) n (%)
Lethargy 38 58 8 12
Peripheral neuropathy 0 2 3
Headache 0 1 2
Oedema 0 1 2
Constipation 10 15 0
Skin rash 2 3 0Continuous low dose Thalidomide in advanced cancer 815
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Of 15 patients who completed serial HAD and Rotterdam
scores, 11 experienced an improvement in sleeping and 14 experi-
enced a maintained or improved appetite. Both of these findings
are statistically significant (P < 0.05), although based on a very
small number of patients.
DISCUSSION
Despite employing a low dose of Thalidomide, we observed
encouraging responses in patients with renal cell carcinoma. In 18
patients treated for renal carcinoma, three showed partial
responses to Thalidomide and 13 showed stable disease, three of
them for more than 3 months. Two of the three responding patients
had progressed on previous biochemotherapy with interferon-a, 5-
fluorouracil and IL-2. Late responses to immunotherapy are seen
both in renal cell carcinoma and in melanoma. However, the
partial responses in these two patients are unlikely to be due to a
late response to biochemotherapy for three reasons. First, patients
were found to have rapidly progressive disease both during 
and after biochemotherapy with disease appearing in previously
A B
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Figure 1 Chest X-ray series illustrating response to Thalidomide after rapid progression on biochemotherapy. (A) At end of biochemotherapy. (B) At start of
Thalidomide 6 weeks later, showing progressive disease. (C) After 2 months of Thalidomide showing PR. (D) After 4 months of Thalidomide showing further PRunaffected sites. Secondly, the patients obtained significant palliative
benefit within 24 h of starting Thalidomide and thirdly, objective
tumour shrinkage started within 2 weeks of starting Thalidomide.
We also observed stable disease in 13 of the remaining 15
patients with renal cell carcinoma. In three of these patients the
stable disease was observed for more than 3 months. These find-
ings may be important as the patients had aggressive and advanced
disease. Four patients with melanoma had stable disease for
periods of up to 5 months and one patient with melanoma experi-
enced significant symptomatic relief from his melanomatous leg
deposits. However, no objective responses were observed in any of
the other patients. Patients found repeated quality of life assess-
ments irksome and this accounts for the poor uptake. The signifi-
cant symptomatic benefits, including improved sleep and appetite,
could be a result of self-selection by those completing the ques-
tionnaires. However, the palliative benefits were credible and
indeed possibly predictable in view of the known sedative and
appetite-enhancing effects of Thalidomide (Powell and Gardner-
Medwin, 1994).
Thalidomide could act either by inhibiting angiogenesis or by
inhibiting factors secreted by the tumour. A humoural basis for the
action of Thalidomide is suggested by the rapid onset of benefit in
our responding patients. The most likely candidate target in renal
cell carcinoma is TNF-a. This cytokine is known to be secreted by
renal cell carcinomas (Mizutani et al, 1994), enhances neo-angio-
genesis (Fajardo et al, 1992), augments the stimulation of renal
carcinoma cells by IL-6 (Koo et al, 1992) and contributes to many
of the systemic symptoms of advanced malignancy (Yoneda et al.,
1991; Haslett, 1998). The inhibition of TNF-a by Thalidomide
may therefore be of particular interest in renal cell carcinoma.
No clear effect of Thalidomide was observed in serial measure-
ments of serum and urine TNF-a, VEGF and bFGF. Free TNF-a
was only detected in the serum of three patients at the time that
their progressive disease was noted. Serum TNF-a levels may
therefore be of limited value in the selection of patients for
Thalidomide treatment or the monitoring of their response. In
future studies we will monitor concentrations of TNF-a in fresh
plasma samples which may be more reliable. The significance of
systemic levels of TNF-a in renal cell carcinoma requires further
investigation. It is possible that local concentrations in the tumour
bed are of greater significance. We found a wide range of serum
and urinary levels of VEGF both in patients and in two controls. In
11 patients who had serial concentrations measured, a rising
VEGF level was found in all six patients with progressive disease.
Similarly, bFGF was only detected in the serum of 12 patients, all
of whom progressed early.
Thalidomide 100 mg orally each night was well tolerated for at
least 11 months even in patients who have previously been treated
with neurotoxic chemotherapy. Two patients who have received
Thalidomide for 11 months and 5 months have developed grade 2
peripheral neuropathy which resolved on interrupting treatment.
Many patients noticed mild lethargy and constipation but none
developed grade 3 or 4 toxicities.
Our findings suggest that Thalidomide may be useful in the
management of advanced renal carcinoma and possibly of sympto-
matic benefit in other solid malignancies. This warrants further
studies, particularly at a higher dose in patients with renal carci-
noma. A fuller appreciation of the effect of Thalidomide on TNF-
a levels is needed because Thalidomide may be of particular
benefit to patients who express high levels of TNF-a. Such a
correlation would allow better selection of patients who may
benefit from this and other anti-angiogenic therapies. Finally, the
use of Thalidomide in combination with other treatments should
be investigated. Highest response rates in renal cell carcinoma are
reported with a combination of interferon-a, 5-fluorouracil and
IL-2 (Lopez-Hanninen et al, 1996). The considerable side-effects
may be related to the finding that IL-2 induces high levels of TNF-
a (Weidmann et al, 1992). The increased levels of TNF-a are
unlikely to contribute to the beneficial effects of this treatment,
since previous experience with TNF-a in renal carcinoma has
shown severe side-effects with a poor response rate (reviewed by
Boshoff and Jones, 1996). Moreover, these high levels of TNF-a
may also stimulate growth of renal carcinoma cells (Lopez-
Hanninen et al, 1996). Interestingly, two of the three patients who
had partial responses to Thalidomide had progressed rapidly on
biochemotherapy for their advanced renal carcinoma. It is
tempting to speculate that these patients’ tumours were responsive
to stimulation with TNF-a and therefore grew rapidly on
biochemotherapy and responded to inhibition of TNF-a by
Thalidomide. There may be a rationale for combining
Thalidomide with biochemotherapy, as a possible way both of
reducing side-effects and increasing the efficacy of treatment for
renal cell carcinoma.
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